Core Viewpoint - Akari Therapeutics is advancing its next-generation antibody drug conjugates (ADCs) with a focus on its proprietary PH1 spliceosome-modulating payload, aiming to initiate first-in-human trials for its lead program, AKTX-101, by late 2026 or early 2027 [2][4]. Company Overview - Akari Therapeutics is an oncology biotechnology company specializing in ADCs that utilize a unique payload, PH1, which targets RNA splicing [4]. - The company has developed a platform that allows for the generation and optimization of ADC candidates tailored to specific antigen targets [4]. Lead Programs - The lead program, AKTX-101, targets the Trop2 receptor on cancer cells and is designed to deliver the PH1 payload directly to tumors with minimal off-target effects [2][4]. - AKTX-101 has shown significant activity in preclinical studies, leading to prolonged survival compared to traditional ADCs [4]. - The company is also advancing AKTX-102, another ADC program focused on gastrointestinal (GI) and lung cancers [2][4]. Upcoming Events - Akari Therapeutics will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026, where CEO Abizer Gaslightwala will present a corporate overview and updates on the company's programs [1][3].

Core Viewpoint - GRI Bio, Inc. is participating in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026, to discuss its innovative pipeline of immune cell modulators for treating inflammatory, fibrotic, and autoimmune diseases [1][2]. Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on transforming the treatment of inflammatory, fibrotic, and autoimmune diseases through therapies targeting Natural Killer T (NKT) cells [3]. - The company's lead program, GRI-0621, is an RARβγ agonist aimed at inhibiting iNKT cell activity and is being developed as an oral therapeutic for idiopathic pulmonary fibrosis, a disease with significant unmet needs [3]. - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its growing pipeline [3]. Webinar Details - The presentation will take place on February 11, 2026, at 1:00 PM EST, led by Marc Hertz, PhD, the President and CEO of GRI Bio [2].

th– Live video webcast on Tuesday, February 10 at 1:20 PM EST â"¢ Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital fr ...

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments [3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which aims to detect and differentiate neural signals with greater sensitivity than current technologies [3] Technology and Applications - The initial focus of the technology is on treating pain, specifically targeting pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4] Upcoming Events - Autonomix will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, scheduled for August 19-21, 2025, with the presentation taking place on August 21, 2025, at 2:20 PM ET [1]

Company Overview - Nuwellis, Inc. is a medical technology company focused on fluid management solutions for critically ill patients [3] - The company is dedicated to transforming the lives of patients suffering from fluid overload through innovation and collaboration [3] - Nuwellis is headquartered in Minneapolis and has a wholly owned subsidiary in Ireland [3] Upcoming Event - Nuwellis will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, held virtually from August 19-21, 2025 [1] - The presentation is scheduled for August 21, 2025, at 2:40 PM ET, and will be led by John Erb, President and CEO [1] - Registration for the event is available through a provided link [1] Industry Context - Webull Financial is a leading online brokerage platform that empowers self-directed investors with innovative tools and technology [2] - The platform offers low-cost trading on a wide range of assets and advanced charting tools, catering to millions of users globally [2] - Webull Financial is registered with the SEC and CFTC, and is a member of FINRA, NFA, and SIPC [2]

Company Overview - Akari Therapeutics is a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for cancer treatment [3] - The company has developed its first novel payload, PH1, which is a spliceosome modulator designed to disrupt RNA splicing within cells [3] - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers the PH1 payload directly into tumors [3] Product Development - PH1 is differentiated from current ADC payloads that typically use Topoisomerase1 inhibitors or tubulin inhibitors, showing potential to induce cancer cell death while activating immune cells [3] - In preclinical studies, AKTX-101 has demonstrated significant activity and prolonged survival compared to traditional ADCs [3] - AKTX-101 has the potential to work synergistically with checkpoint inhibitors, showing prolonged survival both as a single agent and in combination with these inhibitors [3] Upcoming Events - Akari Therapeutics will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 19, 2025, at 2:00 PM ET [1]

Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses [3] - The company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [3] Clinical Trials - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for treating relapsed or refractory AML [4] - Following a successful Phase 1B/2 study (MB-106) and FDA input, the company believes it has de-risked the development pathway for Annamycin's potential approval for AML [4] Additional Drug Development - Moleculin is also developing WP1066, an Immune/Transcription Modulator targeting brain tumors and pancreatic cancers by inhibiting oncogenic transcription factors and stimulating immune response [5] - The company is working on a portfolio of antimetabolites, including WP1122, aimed at treating pathogenic viruses and certain cancer indications [5] Upcoming Events - Moleculin will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 20, 2025, at 2:00 PM ET, with CEO Walter Klemp as the presenter [1]

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [3] Upcoming Presentation - Senti Bio will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 19, 2025, at 2:20 PM ET [1] - The presentation will be led by Timothy Lu, M.D., Ph.D., Co-Founder and CEO of Senti Bio [1] Technology and Pipeline - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting challenging liquid and solid tumor indications [3] - The Gene Circuits have shown preclinical efficacy in both NK and T cells, with potential applications extending beyond oncology [3]

Company Overview - GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on treating inflammatory, fibrotic, and autoimmune diseases through innovative therapies targeting Natural Killer T (NKT) cells [3] - The company's lead program, GRI-0621, is an oral therapeutic aimed at inhibiting iNKT cell activity for the treatment of idiopathic pulmonary fibrosis, addressing a significant unmet medical need [3] - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus, supported by a library of over 500 proprietary compounds [3] Upcoming Presentation - GRI Bio will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech from August 19-21, 2025, with a specific presentation scheduled for August 20, 2025, at 2:20 PM ET [1] - The presentation will be led by Marc Hertz, PhD, who serves as the President, Chief Executive Officer, and Director of GRI Bio [1]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [3] - The company utilizes an innovative ADC discovery platform to generate and optimize ADC candidates for various targets [3] Lead Product Candidate - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers a novel PH1 payload directly into tumors [3] - PH1 is a spliceosome inhibitor designed to disrupt RNA splicing within cancer cells, leading to cancer cell death and activation of immune cells [3] - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs [3] Synergistic Potential - AKTX-101 has shown potential for synergy with checkpoint inhibitors, demonstrating prolonged survival both as a single agent and in combination with these inhibitors [3] Upcoming Presentation - Abizer Gaslightwala, President and CEO of Akari, will present recent corporate events at the Virtual Biotech Investment Webinar on May 29, 2025 [1][2]